Caris Life Sciences' Caris ChromoSeq gets MolDX approval for advanced genome tumor profiling in myeloid cancers.

Caris Life Sciences announced that its Caris ChromoSeq assay received MolDX approval, enabling broader clinical access to this ultra-deep whole genome sequencing test for myeloid malignancies. This approval by the Molecular Diagnostic Services program confirms the test's clinical validity and utility, supporting coverage and reimbursement. Caris ChromoSeq offers comprehensive genomic insights from a single test, replacing multiple assays and aiding diagnosis and treatment decisions for complex myeloid cancers. This milestone enhances patient access to advanced precision medicine diagnostics and supports clinicians with timely, actionable data.